Ruxolitinib + Lenalidomide + Prednisone
Phase 2Completed 1 views this week 0 watching💤 Quiet
Interest: 32/100
32
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Myeloproliferative Diseases
Conditions
Myeloproliferative Diseases
Trial Timeline
Sep 22, 2011 → Sep 5, 2018
NCT ID
NCT01375140About Ruxolitinib + Lenalidomide + Prednisone
Ruxolitinib + Lenalidomide + Prednisone is a phase 2 stage product being developed by Incyte for Myeloproliferative Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT01375140. Target conditions include Myeloproliferative Diseases.
What happened to similar drugs?
0 of 1 similar drugs in Myeloproliferative Diseases were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
12
Activity
8
Company
12
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01375140 | Phase 2 | Completed |
Competing Products
20 competing products in Myeloproliferative Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| LY2784544 | Eli Lilly | Phase 1 | 29 |
| LY2784544 | Eli Lilly | Phase 1 | 29 |
| Navitoclax + Ruxolitinib + Celecoxib | AbbVie | Phase 1 | 33 |
| AUY922 | Novartis | Phase 2 | 27 |
| Pacritinib + Decitabine + Decitabine and Cedazuridine + Azacitidine | Swedish Orphan Biovitrum | Phase 2 | 42 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 2 | 39 |
| VAC85135 + Ipilimumab | Bristol Myers Squibb | Phase 1 | 29 |
| Fedratinib Pill | Bristol Myers Squibb | Phase 1 | 21 |
| Fedratinib Oral Capsule 300 mg + Decitabine 20 mg/m2 + Fedratinib Oral Capsule 400 mg | Bristol Myers Squibb | Phase 1 | 21 |
| Ruxolitinib | Incyte | Phase 2 | 32 |
| Parsaclisib + Parsaclisib + Ruxolitinib + Parsaclisib + Parsaclisib | Incyte | Phase 2 | 24 |
| INCA036978 + Standard disease-directed therapy | Incyte | Phase 1 | 33 |
| Ruxolitinib | Incyte | Phase 2 | 24 |
| Ruxolitinib + Anagrelide + Placebo + Placebo | Incyte | Phase 2 | 24 |
| itacitinib | Incyte | Phase 2 | 32 |
| Ruxolitinib + Placebo | Incyte | Phase 3 | 37 |
| INCB160058 + Standard disease-directed therapy | Incyte | Phase 1 | 33 |
| Pemigatinib | Incyte | Phase 2 | 32 |
| Itacitinib + Ruxolitinib | Incyte | Phase 2 | 32 |
| INCA035784 | Incyte | Phase 1 | 33 |